FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180361166> ?p ?o ?g. }

• W3180361166 abstract "Background Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in fetal life. Recently, researchers have attempted to use anti‐VEGF agents for the treatment of retinopathy of prematurity (ROP), a vasoproliferative disorder. There is currently uncertainty regarding the safety and efficacy of these agents in preterm infants with ROP. Objectives To evaluate the efficacy and safety of anti‐VEGF drugs when used either as monotherapy, i.e. without concomitant cryotherapy or laser therapy or in combination with planned cryo/laser therapy in preterm infants with type 1 ROP (defined as zone I any stage with plus disease, zone I stage 3 with or without plus disease or zone II stage 2 or 3 with plus disease). Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 1), MEDLINE (1966 to January 1, 2016), EMBASE (1980 to January 1, 2016), CINAHL (1982 to January 1, 2016), conference proceedings, and previous reviews. Selection criteria Randomised or quasi‐randomised controlled trials that evaluated the efficacy and safety of administration, or both, of anti‐VEGF agents compared with conventional therapy in premature infants with ROP. Data collection and analysis We used standard Cochrane and Cochrane Neonatal methods for data collection and analysis. Main results Three trials, in which 239 infants participated, fulfilled the inclusion criteria. Two trials compared intravitreal bevacizumab with conventional laser therapy (monotherapy) while the third compared intravitreal pegaptanib plus laser treatment with laser and cryotherapy (combination therapy) in infants with type 1 ROP. Of the two studies that evaluated intravitreal bevacizumab, one randomized infants while the other randomized eyes of the infants to the intervention and control groups. The former did not report any difference in the incidence of complete or partial retinal detachment between the groups (143 infants; RR 1.04, 95% CI 0.21 to 5.13; RD 0.00, 95% CI ‐0.06 to 0.07; very low quality evidence) but reported a significant reduction in the risk of refractive errors ‐ very high myopia ‐ at 30 months of age (211 eyes; RR 0.06, 95% CI 0.02 to 0.20; RD ‐0.40, 95% CI ‐0.50 to ‐0.30; low quality evidence) and recurrence of ROP by 54 weeks' postmenstrual age (143 infants; RR 0.22, 95% CI 0.08 to 0.62; RD ‐0.20, 95% CI ‐0.31 to ‐0.09; moderate quality evidence) in the bevacizumab group. The study found no difference in the risk of mortality before discharge from the hospital (150 infants; RR 1.50; 95% CI 0.26 to 8.75; RD 0.01; 95% CI ‐0.04 to 0.07; low quality evidence), mortality at 30 months of age (150 infants; RR 0.86, 95% CI 0.30 to 2.45; RD ‐0.01; 95% CI ‐0.10 to 0.08; low quality evidence), corneal opacity requiring corneal transplant (286 eyes; RR 0.34, 95% CI 0.01 to 8.26; RD ‐0.01; 95% CI ‐0.03 to 0.02; very low quality evidence), or lens opacity requiring cataract removal (286 eyes; RR 0.15, 95% CI 0.01 to 2.79; RD ‐0.02; 95% CI ‐0.05 to 0.01; very low quality evidence). The second trial that randomized eyes of the infants did not find any difference in the risk of complete retinal detachment between the eyes randomized to bevacizumab and those that were randomized to laser therapy (13 eyes; RR 0.33, 95% CI 0.01 to 7.50; RD ‐0.08, 95% CI ‐0.27 to 0.11). When used in combination with laser therapy, intravitreal pegaptanib was found to reduce the risk of retinal detachment when compared to laser/cryotherapy alone (152 eyes; RR 0.26, 95% CI 0.12 to 0.55; RD ‐0.29, 95% CI ‐0.42 to ‐0.16; low quality evidence). The incidence of recurrence of ROP by 55 weeks' postmenstrual age was also lower in the pegaptanib + laser therapy group (76 infants; RR 0.29, 95% CI 0.12 to 0.7; RD ‐0.35, 95% CI ‐0.55 to ‐0.16; low quality evidence). There was no difference in the risk of perioperative retinal haemorrhages between the two groups (152 eyes; RR 0.62, 95% CI 0.24 to 1.56; RD ‐0.05, 95% CI ‐0.16 to 0.05; very low quality evidence). The risk of delayed systemic adverse effects with either of the drugs is, however, not known. Authors' conclusions Implications for practice: Intravitreal bevacizumab reduces the risk of refractive errors during childhood when used as monotherapy while intravitreal pegaptanib reduces the risk of retinal detachment when used in conjunction with laser therapy in infants with type 1 ROP. Quality of evidence was, however, low for both the outcomes because of the risk of detection and other biases. Effect on other critical outcomes and, more importantly, the long‐term systemic adverse effects of the drugs are not known. The insufficient data precludes strong conclusions favouring routine use of intravitreal anti‐VEGF agents in preterm infants with type 1 ROP. Implications for research: Further studies are needed to evaluate the effect of anti‐VEGF agents on structural and functional outcomes in childhood and delayed systemic adverse effects such as myocardial dysfunction and adverse neurodevelopmental outcomes." @default.
• W3180361166 created "2021-07-19" @default.
• W3180361166 creator A5005816703 @default.
• W3180361166 creator A5034137029 @default.
• W3180361166 creator A5039501674 @default.
• W3180361166 creator A5045329293 @default.
• W3180361166 creator A5072023246 @default.
• W3180361166 date "2016-02-27" @default.
• W3180361166 modified "2023-10-18" @default.
• W3180361166 title "Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity" @default.
• W3180361166 cites W132038692 @default.
• W3180361166 cites W1989993899 @default.
• W3180361166 cites W2008541243 @default.
• W3180361166 cites W2013932535 @default.
• W3180361166 cites W2015291663 @default.
• W3180361166 cites W2025106475 @default.
• W3180361166 cites W2036900916 @default.
• W3180361166 cites W2051098949 @default.
• W3180361166 cites W2058895787 @default.
• W3180361166 cites W2075086348 @default.
• W3180361166 cites W2076695448 @default.
• W3180361166 cites W2083440154 @default.
• W3180361166 cites W2100141665 @default.
• W3180361166 cites W2101535867 @default.
• W3180361166 cites W2110580466 @default.
• W3180361166 cites W2113170046 @default.
• W3180361166 cites W2122805874 @default.
• W3180361166 cites W2125435699 @default.
• W3180361166 cites W2128919242 @default.
• W3180361166 cites W2145523387 @default.
• W3180361166 cites W2157027608 @default.
• W3180361166 cites W2317196257 @default.
• W3180361166 cites W2334508015 @default.
• W3180361166 cites W4231086621 @default.
• W3180361166 cites W4236388884 @default.
• W3180361166 cites W4248231685 @default.
• W3180361166 doi "https://doi.org/10.1002/14651858.cd009734.pub2" @default.
• W3180361166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26932750" @default.
• W3180361166 hasPublicationYear "2016" @default.
• W3180361166 type Work @default.
• W3180361166 sameAs 3180361166 @default.
• W3180361166 citedByCount "35" @default.
• W3180361166 countsByYear W31803611662016 @default.
• W3180361166 countsByYear W31803611662017 @default.
• W3180361166 countsByYear W31803611662018 @default.
• W3180361166 countsByYear W31803611662019 @default.
• W3180361166 countsByYear W31803611662020 @default.
• W3180361166 countsByYear W31803611662021 @default.
• W3180361166 countsByYear W31803611662022 @default.
• W3180361166 countsByYear W31803611662023 @default.
• W3180361166 crossrefType "journal-article" @default.
• W3180361166 hasAuthorship W3180361166A5005816703 @default.
• W3180361166 hasAuthorship W3180361166A5034137029 @default.
• W3180361166 hasAuthorship W3180361166A5039501674 @default.
• W3180361166 hasAuthorship W3180361166A5045329293 @default.
• W3180361166 hasAuthorship W3180361166A5072023246 @default.
• W3180361166 hasConcept C126322002 @default.
• W3180361166 hasConcept C141071460 @default.
• W3180361166 hasConcept C187212893 @default.
• W3180361166 hasConcept C2776694085 @default.
• W3180361166 hasConcept C2776999253 @default.
• W3180361166 hasConcept C2777512022 @default.
• W3180361166 hasConcept C2777802072 @default.
• W3180361166 hasConcept C2778376644 @default.
• W3180361166 hasConcept C2779234561 @default.
• W3180361166 hasConcept C2779918416 @default.
• W3180361166 hasConcept C2780123866 @default.
• W3180361166 hasConcept C2780149145 @default.
• W3180361166 hasConcept C2781100027 @default.
• W3180361166 hasConcept C54355233 @default.
• W3180361166 hasConcept C71924100 @default.
• W3180361166 hasConcept C86803240 @default.
• W3180361166 hasConceptScore W3180361166C126322002 @default.
• W3180361166 hasConceptScore W3180361166C141071460 @default.
• W3180361166 hasConceptScore W3180361166C187212893 @default.
• W3180361166 hasConceptScore W3180361166C2776694085 @default.
• W3180361166 hasConceptScore W3180361166C2776999253 @default.
• W3180361166 hasConceptScore W3180361166C2777512022 @default.
• W3180361166 hasConceptScore W3180361166C2777802072 @default.
• W3180361166 hasConceptScore W3180361166C2778376644 @default.
• W3180361166 hasConceptScore W3180361166C2779234561 @default.
• W3180361166 hasConceptScore W3180361166C2779918416 @default.
• W3180361166 hasConceptScore W3180361166C2780123866 @default.
• W3180361166 hasConceptScore W3180361166C2780149145 @default.
• W3180361166 hasConceptScore W3180361166C2781100027 @default.
• W3180361166 hasConceptScore W3180361166C54355233 @default.
• W3180361166 hasConceptScore W3180361166C71924100 @default.
• W3180361166 hasConceptScore W3180361166C86803240 @default.
• W3180361166 hasLocation W31803611661 @default.
• W3180361166 hasLocation W31803611662 @default.
• W3180361166 hasOpenAccess W3180361166 @default.
• W3180361166 hasPrimaryLocation W31803611661 @default.
• W3180361166 hasRelatedWork W1896852452 @default.
• W3180361166 hasRelatedWork W1977320231 @default.
• W3180361166 hasRelatedWork W2008541243 @default.
• W3180361166 hasRelatedWork W2073586286 @default.
• W3180361166 hasRelatedWork W2382459522 @default.
• W3180361166 hasRelatedWork W2399964584 @default.
• W3180361166 hasRelatedWork W2419020385 @default.
• W3180361166 hasRelatedWork W2744771691 @default.

• next